Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience
Yıl: 2021 Cilt: 6 Sayı: 2 Sayfa Aralığı: 44 - 50 Metin Dili: İngilizce DOI: 10.26663/cts.2021.0009 İndeks Tarihi: 27-05-2022
Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience
Öz: Background: Ewing sarcoma (ES) is an uncommon aggressive malignant tumor of the bone and/or
soft tissue and belongs to peripheral primitive neuroectodermal tumor (PNET) family of tumors. Bone
PNETs primarily arise from the diaphysis of long bones, where as soft tissue PNETs are most commonly
found in the chest wall. Multidisciplinary treatments, including chemotherapy, surgery, radiotherapy, or
all three combined, improve the survival of patients with localized ES. However, the best approach to
achieve local control remains controversial.
Materials and Methods: We retrospectively analysed the medical records and pathology data of 14
patients (8 male, 6 female; mean age, 23.2 [range, 4-54] years) with primary thoracic ES who underwent
surgery in our clinic between January 2002 and December 2019. In addition, the treatment modalities
and tumor-related factors of chest wall ES and lung parenchyma were evaluated.
Results: The most frequent complaint was chest pain (n = 7). In 10 patients, the tumor originated
from the ribs, whereas the remaining 4 patients had lung parenchymal tumors. Ten patients underwent
complete tumor excision with chest wall resection, one patient underwent lower lobectomy with chest
wall resection, and three patients underwent complete tumor excision via wedge resection. All patients
were treated with chemotherapy, except two who underwent bone marrow transplantation. The median
follow-up was 31.6 (range, 2-84) months. Relapses were seen in 5 cases in the median 19.8th (range,
4-60) month.
Conclusions: Complete tumor resection is the most effective treatment for thoracic ES and multimodal
therapy (surgical resection, chemotherapy, and local radiation therapy), which is recommended
when indicated, constitutes the optimal treatment for ES. Although relapses occur within the early
postoperative period, late relapses are not uncommon. The follow-up periods must be short and should
be maintained long term for late relapses.
Anahtar Kelime: Primer torasik Ewing sarkomu diğerlerinden daha agresif midir? On yedi yıllık deneyim
Öz: Arka plan: Ewing sarkomu (ES), kemik ve/veya kemiğin nadir görülen agresif malign bir tümörüdür.
yumuşak dokudur ve periferik ilkel nöroektodermal tümör (PNET) tümör ailesine aittir. Kemik
PNET'ler öncelikle uzun kemiklerin diyafizinden kaynaklanır, burada yumuşak doku PNET'leri en yaygın olarak bulunur.
göğüs duvarında bulunur. Kemoterapi, cerrahi, radyoterapi veya
üçü bir arada, lokalize ES'li hastaların sağkalımını iyileştirir. Bununla birlikte, en iyi yaklaşım
yerel kontrolün sağlanması tartışmalı olmaya devam etmektedir.
Gereç ve Yöntem: 14 hastanın tıbbi kayıtları ve patoloji verileri geriye dönük olarak analiz edildi.
primer torasik ES'li hastalar (8 erkek, 6 kadın; ortalama yaş, 23.2 [aralık, 4-54] yıl)
Ocak 2002-Aralık 2019 tarihleri arasında kliniğimizde ameliyat edilmiştir. Ayrıca tedavi modaliteleri
göğüs duvarı ES ve akciğer parankiminin tümörle ilişkili faktörleri değerlendirildi.
Bulgular: En sık yakınma göğüs ağrısıydı (n=7). 10 hastada tümör kaynaklı
kaburgalardan, kalan 4 hastada ise akciğer parankimal tümörleri vardı. On hastaya uygulandı
göğüs duvarı rezeksiyonu ile tam tümör eksizyonu, bir hastaya göğüs ile alt lobektomi uygulandı
duvar rezeksiyonu ve üç hastaya wedge rezeksiyon yoluyla tam tümör eksizyonu uygulandı. tüm hastalar
kemik iliği nakli yapılan iki hasta dışında kemoterapi ile tedavi edildi. ortanca
takip süresi 31.6 (aralık, 2-84) aydı. Ortanca 19.8'de 5 vakada nüks görüldü (aralık,
4-60) ay.
Sonuçlar: Tam tümör rezeksiyonu torasik ES ve multimodal için en etkili tedavidir.
önerilen tedavi (cerrahi rezeksiyon, kemoterapi ve lokal radyasyon tedavisi)
endike olduğunda, ES için optimal tedaviyi oluşturur. Erken dönemde nüksler oluşsa da
postoperatif dönemde, geç nüksler nadir değildir. Takip süreleri kısa olmalı ve
geç nüksler için uzun süreli muhafaza edilmelidir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Provost B, Missenard G, Pricopi C, Mercier 3, Mussot S, Fabre D et al. Ewing Sarcoma of the Chest Wall: Prognostic Factors of Multimodal Therapy Including En Bloc Resection. Ann Thorac Surg 2018; 106: 207-13.
- 2. Denbo J, Orr WS, Wu Y, Wu J, Billups CA, Navid F et al. Timing of Surgery and the Role of Adjuvant Radiation Therapy in Ewing Sarcoma of the Chest Wall: A Single Institution Experience. Ann Surg Oncol 2012; 19: 3809-15.
- 3. Hancorn K, Sharma A, Shackcloth M. Primary extraskeletal Ewing’s sarcoma of the lung. Interact Cardiovasc Thorac Surg 2010; 10; 803-4.
- 4. Jedlicka P. Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol 2010; 19: 338-47.
- 5. Seker MM, Kos T, Ozdemir N, Seker A, Aksoy S, Uncu D et al. Treatment and Outcomes of Ewing Sarcoma in Turkish Adults: A Single Centre Experience. Asian Pac J Cancer Prev 2014; 15: 327-30.
- 6. Tsokos M, Alaggio RD, Dehner LP, Dickman PS. Ewing sarcoma/peripheral primitive neuroectodermal tumor and related tumors. Pediatr Dev Pathol 2012; 15: 108-26.
- 7. Zoubek A, Simonitsch I, Panzer-Grümayer ER, Ghali D, Pfleiderer C, Haas OA et al. Ewing tumor after treatment of Ki-1+ anaplastic large cell lymphoma: therapy associated secondary neoplasm or unrelated coincidence? Cancer Genet Cytogenet 1995; 83: 5-11.
- 8. Spunt SL, Rodriguez-Galindo C, Fuller CE, Harper J, Krasin MJ, Billups CA et al. Ewing sarcoma family tumors that arise after treatment of primary childhood cancer. Cancer 2006; 107: 201-6.
- 9. Cavazzana AO, Ninfo V, Roberts J, Triche TJ. Peripheral neuroepithelioma: a light microscopic, immunocytochemical, and ultrastructural study. Mod Pathol 1992; 5: 71-8.
- 10. Holcombe EG. The Ewing Family of Tumors: Ewing’s Sarcoma and Primitive Neuroectodermal Tumors. Pediatr Clin North Am 1997; 44: 991-1004.
- 11. Takahashi D, Nagayama J, Nagatoshi Y, Nishiyama M, Yokoyama R, Moriyasu Y et al. Primary Ewing’s sarcoma family tumors of the lung a case report and review of the literature. Jpn J Clin Oncol 2007; 37: 874 -7.
- 12. Schuck A, Hofmann J, Rübe C, Hillmann A, Ahrens S, Paulussen M et al. Radiotherapy in Ewing’s sarcoma and PNET of the chest wall: results of the trials CESS 81, CESS 86 and EICESS 92. Int J Radiat Oncol Biol Phys 1998; 42: 1001-6.
- 13. Castex MP, Rubie H, Stevens MCG, Gauzy JS, Brouchet AG, Rey A et al. Extraosseous localized Ewing tumours: improved outcome with anthracyclines. The French Society of Pediatric Oncology and International Society of Pediatric Oncology. J Clin Oncol 2007; 25: 1176-82.
- 14. .Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol 2009; 27: 2536-41.
- 15. Denbo JW, Orr WS, Wu Y, Wu J, Billups CA, Navid F et al. Timing of surgery and the role of adjuvant radiotherapy in ewing sarcoma of the chest wall: a single-institution experience. Ann Surg Oncol 2012; 19: 3809-15.
- 16. Lin PP, Jaffe N, Herzog CE, Costelloe CM, Deavers MT, Kelly JS et al. Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer 2007; 109: 603-11.
- 17. Womer RB, West DC, Krailo MD, Dickman PS, Pawel B. Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT). J Clin Oncol 2008; 26: 10504.
- 18. Denbo JW, Orr WS, Wu Y, Wu J, Billups CA, Navid F et al. Timing of Surgery and the Role of Adjuvant Radiation Therapy in Ewing Sarcoma of the Chest Wall: A Single Institution Experience. Ann Surg Oncol 2012; 19: 3809-15.
- 19. Shamberger RC, LaQuaglia MP, Gebhardt MC, Neff JR, Tarbell NJ, Marcus KC et al. Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Chest Wall. Impact of Initial versus Delayed Resection on Tumor Margins, Survival, and Use of Radiation Therapy. Ann Surg 2003; 238: 563-8.
APA | hazer s, findik g, aydoğdu k, AGAÇKIRAN Y, Gulhan S, Demiröz Ş, bıçakcıoğlu p, KAYA S (2021). Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience. , 44 - 50. 10.26663/cts.2021.0009 |
Chicago | hazer seray,findik gokturk,aydoğdu koray,AGAÇKIRAN YETKIN,Gulhan Selim Sakir Erkmen,Demiröz Şevki Mustafa,bıçakcıoğlu pınar,KAYA Sadi Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience. (2021): 44 - 50. 10.26663/cts.2021.0009 |
MLA | hazer seray,findik gokturk,aydoğdu koray,AGAÇKIRAN YETKIN,Gulhan Selim Sakir Erkmen,Demiröz Şevki Mustafa,bıçakcıoğlu pınar,KAYA Sadi Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience. , 2021, ss.44 - 50. 10.26663/cts.2021.0009 |
AMA | hazer s,findik g,aydoğdu k,AGAÇKIRAN Y,Gulhan S,Demiröz Ş,bıçakcıoğlu p,KAYA S Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience. . 2021; 44 - 50. 10.26663/cts.2021.0009 |
Vancouver | hazer s,findik g,aydoğdu k,AGAÇKIRAN Y,Gulhan S,Demiröz Ş,bıçakcıoğlu p,KAYA S Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience. . 2021; 44 - 50. 10.26663/cts.2021.0009 |
IEEE | hazer s,findik g,aydoğdu k,AGAÇKIRAN Y,Gulhan S,Demiröz Ş,bıçakcıoğlu p,KAYA S "Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience." , ss.44 - 50, 2021. 10.26663/cts.2021.0009 |
ISNAD | hazer, seray vd. "Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience". (2021), 44-50. https://doi.org/10.26663/cts.2021.0009 |
APA | hazer s, findik g, aydoğdu k, AGAÇKIRAN Y, Gulhan S, Demiröz Ş, bıçakcıoğlu p, KAYA S (2021). Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience. Current Thoracic Surgery, 6(2), 44 - 50. 10.26663/cts.2021.0009 |
Chicago | hazer seray,findik gokturk,aydoğdu koray,AGAÇKIRAN YETKIN,Gulhan Selim Sakir Erkmen,Demiröz Şevki Mustafa,bıçakcıoğlu pınar,KAYA Sadi Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience. Current Thoracic Surgery 6, no.2 (2021): 44 - 50. 10.26663/cts.2021.0009 |
MLA | hazer seray,findik gokturk,aydoğdu koray,AGAÇKIRAN YETKIN,Gulhan Selim Sakir Erkmen,Demiröz Şevki Mustafa,bıçakcıoğlu pınar,KAYA Sadi Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience. Current Thoracic Surgery, vol.6, no.2, 2021, ss.44 - 50. 10.26663/cts.2021.0009 |
AMA | hazer s,findik g,aydoğdu k,AGAÇKIRAN Y,Gulhan S,Demiröz Ş,bıçakcıoğlu p,KAYA S Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience. Current Thoracic Surgery. 2021; 6(2): 44 - 50. 10.26663/cts.2021.0009 |
Vancouver | hazer s,findik g,aydoğdu k,AGAÇKIRAN Y,Gulhan S,Demiröz Ş,bıçakcıoğlu p,KAYA S Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience. Current Thoracic Surgery. 2021; 6(2): 44 - 50. 10.26663/cts.2021.0009 |
IEEE | hazer s,findik g,aydoğdu k,AGAÇKIRAN Y,Gulhan S,Demiröz Ş,bıçakcıoğlu p,KAYA S "Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience." Current Thoracic Surgery, 6, ss.44 - 50, 2021. 10.26663/cts.2021.0009 |
ISNAD | hazer, seray vd. "Is primary thoracic Ewing sarcoma aggressive than others? Seventeenyears’ experience". Current Thoracic Surgery 6/2 (2021), 44-50. https://doi.org/10.26663/cts.2021.0009 |